Not yet- company is making a lot of money! if you where to cut - where would you start?To keep investors happy, layoffs will happen
Not yet- company is making a lot of money! if you where to cut - where would you start?
Bloated sales force will be first to go!,Not yet- company is making a lot of money! if you where to cut - where would you start?
Buying stuff may work for a while, but it is not sustainable in the long term. Problem is, if you don't have some internal innovation, you make bad decisions on external innovation. Either that or you overpay. Whether it's manufacturing, clinical trials, or research/innovation, it is pretty hard to effectively outsource something if you are not already good it at yourself.Poster above isn’t wrong about lack of internal innovation.
beyond inventing patent thickets, Abbott/vie doesn’t invent new stuff. this is a company that just buys other people’s stuff. At best they run a phase 3, but recently they just buy approved crap and lawyer it up.
nothing wrong with that, but they sunk a ton into r and d post split to try to prove they weren’t like Abbott. Time to liquidate all that stuff.
If they were good add it, why do they need to buy innovation?Buying stuff may work for a while, but it is not sustainable in the long term. Problem is, if you don't have some internal innovation, you make bad decisions on external innovation. Either that or you overpay. Whether it's manufacturing, clinical trials, or research/innovation, it is pretty hard to effectively outsource something if you are not already good it at yourself.
If they were good add it, why do they need to buy innovation?
If they could run phase 3s and register products, why the recent crl that puts off approval until 2024 according to earnings update?
This is not an R&D organization and nothing wrong with that. Be thankful for the financial means to buy innovation and provide on market support.
Time will tell if we can catch lightning in a bottle yet again.If they were good add it, why do they need to buy innovation?
If they could run phase 3s and register products, why the recent crl that puts off approval until 2024 according to earnings update?
This is not an R&D organization and nothing wrong with that. Be thankful for the financial means to buy innovation and provide on market support.
I'm not saying you can't buy innovation, I'm saying you can't buy what you don't understand. The numbers speak volumes: Abbvie acquired BASF/Knoll for 6 billion and got Humira. No wait, ABBOTT acquired them, ABBVIE did the Allergan deal for 60 billion. Think something like Humira will come out of that?If they were good add it, why do they need to buy innovation?
If they could run phase 3s and register products, why the recent crl that puts off approval until 2024 according to earnings update?
This is not an R&D organization and nothing wrong with that. Be thankful for the financial means to buy innovation and provide on market support.
It’s even worse when you think you are good, when really you were just lucky.Let’s face it, humira made a lot of mediocre people look competent. Classic example of better to be lucky than good. Just ask the college dropout.
Fuck off. That is fact.There is no luck in acquiring Humira, Skyrizi and Imbruvica. That is making right bets. That is sorting thru all the crap that could be bought and picking a winner. Same thing goes for the Allergan acquisition - you get Botox, vraylar, ubrelvy and qulipta for a bargain.
Abbott/AbbVie knows how to acquire products and maximizes the return on investment with excellent commercial execution. That is a fact.
Now Knoll, Pharmacyclics and Allergan, the ‘golden geese’ will never lay another egg now that they have shacked up with Abbott Park. They are or will be permanently sterilized as they learn to do things the AbbVie way. The scientists that came over from Knoll or Pharmacyclics - have they been able to produce anything with all the resources they could only dream about as standalone companies. No. That is fact. And the same will go for Allergan scientists. AbbVie does not an innovator culture. AbbVie leadership shoves their losing way down peoples throat, look exodus happening over the last year. You can’t be ultra risk averse and discover new first in class medicines. It’s an oxymoron. You also can’t have the incompetent R&D leadership that rules AbbVie.
There is no luck in acquiring Humira, Skyrizi and Imbruvica. That is making right bets. That is sorting thru all the crap that could be bought and picking a winner. Same thing goes for the Allergan acquisition - you get Botox, vraylar, ubrelvy and qulipta for a bargain.
Abbott/AbbVie knows how to acquire products and maximizes the return on investment with excellent commercial execution. That is a fact.
Now Knoll, Pharmacyclics and Allergan, the ‘golden geese’ will never lay another egg now that they have shacked up with Abbott Park. They are or will be permanently sterilized as they learn to do things the AbbVie way. The scientists that came over from Knoll or Pharmacyclics - have they been able to produce anything with all the resources they could only dream about as standalone companies. No. That is fact. And the same will go for Allergan scientists. AbbVie does not an innovator culture. AbbVie leadership shoves their losing way down peoples throat, look exodus happening over the last year. You can’t be ultra risk averse and discover new first in class medicines. It’s an oxymoron. You also can’t have the incompetent R&D leadership that rules AbbVie.
